Under the terms of the agreement, Roche’s exclusive rights to sell and distribute the ProbeLibrary products are extended on a co-exclusive basis. In addition, Roche obtains co-exclusive rights to use the Universal ProbeLibrary (UPL) for the development and manufacturing of its new line of RealTime ready qPCR assays.
With the RealTime ready assay line, Roche Applied Science will offer a fully customizable portfolio of validated target specific gene expression assays for quantitative polymerase chain reaction (PCR) in single assay format and multiwell plate format, pre-plated in 96 and 384 well qPCR plates for the LightCycler system.
Lars Kongsbak, president and CEO of Exiqon, said: “This extension of our partnership with Roche allows the application of the technology of for Exiqon’s LNA detection in the new and fast growing market for ready-to-use and customizable RealTime PCR products.”